Literature DB >> 32253272

The Value of Intravenous Iron: Beyond the Cave of Speculation.

Daniel W Coyne1, Steven Fishbane2.   

Abstract

Entities:  

Keywords:  Hemodialysis hazards; anemia; cardiovascular events; infection

Mesh：

Substances：

Year:  2020        PMID： 32253272      PMCID： PMC7217414          DOI： 10.1681/ASN.2019121340

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  10 in total

1.  Iron treatment: impact of safety issues.

Authors:  S Fishbane
Journal:  Am J Kidney Dis       Date:  1998-12       Impact factor: 8.860

Review 2.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

3.  Intravenous Iron Use in the Care of Patients with Kidney Disease.

Authors:  Iain C Macdougall
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-07       Impact factor: 8.237

4.  Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.

Authors:  Nosratola D Vaziri
Journal:  Am J Med       Date:  2012-07-13       Impact factor: 4.965

5.  Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.

Authors:  Iain C Macdougall; Sunil Bhandari; Claire White; Stefan D Anker; Kenneth Farrington; Philip A Kalra; Patrick B Mark; John J V McMurray; Chante Reid; Michele Robertson; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121

6.  Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.

Authors:  Daniel W Coyne; Toros Kapoian; Wadi Suki; Ajay K Singh; John E Moran; Naomi V Dahl; Adel R Rizkala
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

Review 7.  Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Authors:  Stefan D Anker; Bridget-Anne Kirwan; Dirk J van Veldhuisen; Gerasimos Filippatos; Josep Comin-Colet; Frank Ruschitzka; Thomas F Lüscher; Gregory P Arutyunov; Michael Motro; Claudio Mori; Bernard Roubert; Stuart J Pocock; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2017-04-24       Impact factor: 15.534

8.  Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.

Authors:  A K Singh; D W Coyne; W Shapiro; A R Rizkala
Journal:  Kidney Int       Date:  2007-03-28       Impact factor: 10.612

9.  Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.

Authors:  Lillian A Rocha; Daniela V Barreto; Fellype C Barreto; Cristiane B Dias; Rosa Moysés; Maria Regina R Silva; Luiz A R Moura; Sérgio A Draibe; Vanda Jorgetti; Aluízio B Carvalho; Maria Eugênia F Canziani
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-08       Impact factor: 8.237

10.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Authors:  Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  N Engl J Med       Date:  2018-10-26       Impact factor: 91.245
  10 in total
  1 in total

1.  Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO.

Authors:  Daniel W Coyne
Journal:  Kidney360       Date:  2021-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.